Logo

Roche's Xofluza (baloxavir marboxil) Receives CHMP's Recommendation for Approval to Treat Influenza

Share this
Roche's Xofluza (baloxavir marboxil) Receives CHMP's Recommendation for Approval to Treat Influenza

Roche's Xofluza (baloxavir marboxil) Receives CHMP's Recommendation for Approval to Treat Influenza

Shots:

  • The EMA’s CHMP has recommended the approval of Xofluza (baloxavir marboxil) for the treatment of uncomplicated influenza in patients aged ≥12yrs. Xofluza has also been recommended for approval as a preventive treatment (post-exposure prophylaxis) of influenza in individuals aged ≥12yrs.
  • The CHMP recommendation is based on the results of the P-III CAPSTONE-1- CAPSTONE-2 and BLOCKSTONE studies. The company is expecting the EC’s final decision in approval in the near future
  • Xofluza is the first in a class of antivirals designed to inhibit the cap-dependent endonuclease protein and is available in the US and in several other countries for influenza types A and B

­ Ref: Roche | Image: Roche

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions